Spotlight on Neurology
Rethinking Migraine Treatment: New Therapies Impacting Patient Care
StartActivity Details
Expires: July 14, 2020
Accredited By
Target Audience
This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
- Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
- Discuss unmet patient needs and burden of episodic and chronic migraine.
- Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.
Activity Description
The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.
Statement of Educational Need
With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).
Agenda
The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine
Faculty
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must
demonstrate balance, independence, and scientific rigor. All those in a
position to control the content of an activity must disclose all relevant
financial relationship(s) with commercial interest(s)*. For this educational
activity, all conflicts of interest have been resolved through peer review
and revisions to ensure independence, evidence base, fair balance, and
absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest
as any entity producing, marketing, reselling, or distributing healthcare
goods or services consumed by or used on patients. The ACCME does not
consider providers of clinical service directly to patients to be commercial
interests.
The following individuals have disclosed that they and/or their
spouse/partner has had a financial relationship in the past 12 months:
- Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
- Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:
- Faculty: Ana Felix, MD, FAAN
- Planner (Forefront Collaborative):Krista Jaworski
Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
Content Review Statement
The content of this activity was independently peer reviewed. The reviewer
of this activity has no relevant financial relationships to disclose.
This continuing medical education activity will include reference to
unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions about the Activity
Krista_jaworski@forefrontcollab.com
812-340-4274
Activity Details
Expires: July 14, 2020
Accredited By
Target Audience
This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
- Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
- Discuss unmet patient needs and burden of episodic and chronic migraine.
- Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.
Activity Description
The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.
Statement of Educational Need
With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).
Agenda
The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine
Faculty
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must
demonstrate balance, independence, and scientific rigor. All those in a
position to control the content of an activity must disclose all relevant
financial relationship(s) with commercial interest(s)*. For this educational
activity, all conflicts of interest have been resolved through peer review
and revisions to ensure independence, evidence base, fair balance, and
absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest
as any entity producing, marketing, reselling, or distributing healthcare
goods or services consumed by or used on patients. The ACCME does not
consider providers of clinical service directly to patients to be commercial
interests.
The following individuals have disclosed that they and/or their
spouse/partner has had a financial relationship in the past 12 months:
- Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
- Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:
- Faculty: Ana Felix, MD, FAAN
- Planner (Forefront Collaborative):Krista Jaworski
Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
Content Review Statement
The content of this activity was independently peer reviewed. The reviewer
of this activity has no relevant financial relationships to disclose.
This continuing medical education activity will include reference to
unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions about the Activity
Krista_jaworski@forefrontcollab.com
812-340-4274
Neurology Presentations
Gene Therapy: A Landmark in Spinal Muscular Atrophy Treatment
StartActivity Details
Expires: August 28, 2020
Accredited By
Target Audience
This activity is intended for neurologists, neuromuscular specialists, and pediatric neurologists.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain how gene therapy works
- Explain the potential implications of gene therapy for SMA
- Summarize key clinical trial data on emerging treatments for SMA, with a focus on gene therapy
Activity Description
This multi-media activity will explore the latest in SMA treatment, including the newly approved gene therapy. Hear from 3 experts in the field as they explain what you need to know about this treatment. Hear answers to the most frequently asked questions on this topic and access tools and resources you will be able to use in your practice today.
Statement of Educational Need
Spinal muscular atrophy (SMA) is the most common fatal genetic disease of children under 2 years old, though gene therapy has led to babies hitting unprecedented motor milestones and living longer. The first gene therapy is now available to treat SMA and it is critical that clinicians are prepared to administer this treatment.
Faculty
Professor of Pediatrics and Neurology
University of Connecticut School of Medicine
Division Head, Neurology
Connecticut Children’s Medical Center
Farmington, CT
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Children’s Hospital Colorado
Professor of Clinical Pediatrics and Neurology
University of Colorado
Aurora, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Faculty Disclosures-Content
Creators
The faculty listed below report that they have no relevant financial
relationships to disclose:
- Wendy K. Chung, MD, PhD
The following faculty report that they have relevant financial relationships to disclose:
- Gyula Acsadi, MD, PhD, reports that he has done consulting for Biogen, Serepta, and AveXis; served on a Speakers Bureau for Biogen; and has done contract research for Biogen, Serepta, and Italfarmaco.
- Julie Parsons, MD, reports that she has served on advisory boards for AveXis, Biogen, and Genentech. She has done contract research for AveXis, Biogen, Scholar Rock, and Cytokinetics.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this
enduring activity for a maximum of 0.5 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME-accredited
provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions about the Activity
For questions about the activity, please contact The France Foundation at
Activity Details
Expires: August 28, 2020
Accredited By
Target Audience
This activity is intended for neurologists, neuromuscular specialists, and pediatric neurologists.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain how gene therapy works
- Explain the potential implications of gene therapy for SMA
- Summarize key clinical trial data on emerging treatments for SMA, with a focus on gene therapy
Activity Description
This multi-media activity will explore the latest in SMA treatment, including the newly approved gene therapy. Hear from 3 experts in the field as they explain what you need to know about this treatment. Hear answers to the most frequently asked questions on this topic and access tools and resources you will be able to use in your practice today.
Statement of Educational Need
Spinal muscular atrophy (SMA) is the most common fatal genetic disease of children under 2 years old, though gene therapy has led to babies hitting unprecedented motor milestones and living longer. The first gene therapy is now available to treat SMA and it is critical that clinicians are prepared to administer this treatment.
Faculty
Professor of Pediatrics and Neurology
University of Connecticut School of Medicine
Division Head, Neurology
Connecticut Children’s Medical Center
Farmington, CT
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
Co-Director, Neuromuscular Clinic
Haberfeld Family Endowed Chair in Pediatric Neuromuscular Disorders
Children’s Hospital Colorado
Professor of Clinical Pediatrics and Neurology
University of Colorado
Aurora, CO
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Faculty Disclosures-Content
Creators
The faculty listed below report that they have no relevant financial
relationships to disclose:
- Wendy K. Chung, MD, PhD
The following faculty report that they have relevant financial relationships to disclose:
- Gyula Acsadi, MD, PhD, reports that he has done consulting for Biogen, Serepta, and AveXis; served on a Speakers Bureau for Biogen; and has done contract research for Biogen, Serepta, and Italfarmaco.
- Julie Parsons, MD, reports that she has served on advisory boards for AveXis, Biogen, and Genentech. She has done contract research for AveXis, Biogen, Scholar Rock, and Cytokinetics.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this
enduring activity for a maximum of 0.5 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME-accredited
provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis.
Disclaimer Statement/ Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information for Questions about the Activity
For questions about the activity, please contact The France Foundation at
The Changing Landscape of SMA—From Anaheim, CA
StartActivity Details
Expires: July 30, 2020
Accredited By
Target Audience
Neurologists, genetic counselors, neuromuscular specialists, nurses, and nurse practitioners
Learning Objectives
After completing this activity, the participant should be better able to:
- Review information on the management of patients with SMA released at major conferences in 2019
- Apply emerging information to current SMA management practices, as relevant
Activity Description
Researchers and clinicians interested in spinal muscular atrophy gathered for a conference discussing this serious genetic neuromuscular disorder. Experts share the clinical implications of new information presented at this meeting in this enduring activity.
Statement of Educational Need
The rapid influx of new information surrounding treatment for SMA has created a gap in clinician knowledge and the ability to apply it to practice.
Agenda
- More Options Make Treatment Decisions More Complex
- Efficacy Studies Advocate for the Importance of Newborn Screening
- Don’t Forget the SMA Standards of Care
- Potential Treatment for Fatigue
- Potential Biomarkers for Symptom Onset and Treatment Response
- Challenges and Ethical Considerations When Treating Adults
- Implications of Risdiplam Clinical Trials
- Nusinersen Studies Continue to Show Efficacy and Safety
- Treatment Comparison Caveats and Combination Therapy
Faculty
Pediatric Neuromuscular Specialist
University of Texas, Southwestern
Dallas, TX
- Dr. Castro has done contract research for AveXis, Biogen, PTC, Sarepta, and ReveraGen BioPharma.
Associate Neurologist-in-Chief
Boston Children’s Hospital
Boston, MA
- Dr. Darras serves on advisory boards for AveXis, Biogen, Cytokinetics, Dynacure, PTC, Roche, Genentech, and Sarepta. He receives research support from National Institutes of Health/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, Working on Walking Fund, and the SMA Foundation; grants from CureSMA, Ionis Pharmaceuticals, Inc. and Biogen during ENDEAR, CHERISH, CS2, CS12, CS11 studies, AveXis, Cytokinetics, Fibrogen, PTC, Roche, Santhera, Sarepta, and Summit. He receives royalties from UpToDate and Elsevier.
Co-Director of the Neuromuscular Clinic
Children’s Hospital Colorado
Aurora, CO
- Dr. Parsons has served on advisory boards for AveXis, Biogen, and Genentech/Roche. She has done contract research for AveXis, Biogen, Cytokinetics, and Scholar Rock.
Associate Professor of Neurology
UCLA Medical Center
Los Angeles, CA
- Dr. Shieh has done non-CE consulting for AveXis, Biogen, Genentech, PTC, and Sarepta. He serves on speakers’ bureaus for Alexion, AMO Pharma, Behring, Biogen, CSL, and Grifols. He does contract research for Acceleron, Audentes, Avexis, Biogen, Catabasis, Catalyst, Cytokinetics, Italfarmico, Pfizer, PTC, Ra Pharma, Reata, ReveraGen BioPharma, Roche, Sanofi, Santhera, Sarepta, and Summit.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this
enduring activity for a maximum of 0.50 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Nurses
Nurses who are certified by the American
Nurses Credentialing Center (ANCC) may utilize activities that are certified
by ACCME-accredited providers toward their requirement for certification
renewal by the ANCC. A certificate of attendance will be provided by The
France Foundation, an ACCME accredited provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by educational grants from Biogen and Genentech, Inc.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Activity Details
Expires: July 30, 2020
Accredited By
Target Audience
Neurologists, genetic counselors, neuromuscular specialists, nurses, and nurse practitioners
Learning Objectives
After completing this activity, the participant should be better able to:
- Review information on the management of patients with SMA released at major conferences in 2019
- Apply emerging information to current SMA management practices, as relevant
Activity Description
Researchers and clinicians interested in spinal muscular atrophy gathered for a conference discussing this serious genetic neuromuscular disorder. Experts share the clinical implications of new information presented at this meeting in this enduring activity.
Statement of Educational Need
The rapid influx of new information surrounding treatment for SMA has created a gap in clinician knowledge and the ability to apply it to practice.
Agenda
- More Options Make Treatment Decisions More Complex
- Efficacy Studies Advocate for the Importance of Newborn Screening
- Don’t Forget the SMA Standards of Care
- Potential Treatment for Fatigue
- Potential Biomarkers for Symptom Onset and Treatment Response
- Challenges and Ethical Considerations When Treating Adults
- Implications of Risdiplam Clinical Trials
- Nusinersen Studies Continue to Show Efficacy and Safety
- Treatment Comparison Caveats and Combination Therapy
Faculty
Pediatric Neuromuscular Specialist
University of Texas, Southwestern
Dallas, TX
- Dr. Castro has done contract research for AveXis, Biogen, PTC, Sarepta, and ReveraGen BioPharma.
Associate Neurologist-in-Chief
Boston Children’s Hospital
Boston, MA
- Dr. Darras serves on advisory boards for AveXis, Biogen, Cytokinetics, Dynacure, PTC, Roche, Genentech, and Sarepta. He receives research support from National Institutes of Health/National Institute of Neurological Disorders and Stroke, the Slaney Family Fund for SMA, Working on Walking Fund, and the SMA Foundation; grants from CureSMA, Ionis Pharmaceuticals, Inc. and Biogen during ENDEAR, CHERISH, CS2, CS12, CS11 studies, AveXis, Cytokinetics, Fibrogen, PTC, Roche, Santhera, Sarepta, and Summit. He receives royalties from UpToDate and Elsevier.
Co-Director of the Neuromuscular Clinic
Children’s Hospital Colorado
Aurora, CO
- Dr. Parsons has served on advisory boards for AveXis, Biogen, and Genentech/Roche. She has done contract research for AveXis, Biogen, Cytokinetics, and Scholar Rock.
Associate Professor of Neurology
UCLA Medical Center
Los Angeles, CA
- Dr. Shieh has done non-CE consulting for AveXis, Biogen, Genentech, PTC, and Sarepta. He serves on speakers’ bureaus for Alexion, AMO Pharma, Behring, Biogen, CSL, and Grifols. He does contract research for Acceleron, Audentes, Avexis, Biogen, Catabasis, Catalyst, Cytokinetics, Italfarmico, Pfizer, PTC, Ra Pharma, Reata, ReveraGen BioPharma, Roche, Sanofi, Santhera, Sarepta, and Summit.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this
enduring activity for a maximum of 0.50 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate
with the extent of their participation in the activity.
Nurses
Nurses who are certified by the American
Nurses Credentialing Center (ANCC) may utilize activities that are certified
by ACCME-accredited providers toward their requirement for certification
renewal by the ANCC. A certificate of attendance will be provided by The
France Foundation, an ACCME accredited provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity.
- Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by educational grants from Biogen and Genentech, Inc.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Rethinking Migraine Treatment: New Therapies Impacting Patient Care
StartActivity Details
Expires: July 14, 2020
Accredited By
Target Audience
This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
- Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
- Discuss unmet patient needs and burden of episodic and chronic migraine.
- Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.
Activity Description
The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.
Statement of Educational Need
With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).
Agenda
The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine
Faculty
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must
demonstrate balance, independence, and scientific rigor. All those in a
position to control the content of an activity must disclose all relevant
financial relationship(s) with commercial interest(s)*. For this educational
activity, all conflicts of interest have been resolved through peer review
and revisions to ensure independence, evidence base, fair balance, and
absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest
as any entity producing, marketing, reselling, or distributing healthcare
goods or services consumed by or used on patients. The ACCME does not
consider providers of clinical service directly to patients to be commercial
interests.
The following individuals have disclosed that they and/or their
spouse/partner has had a financial relationship in the past 12 months:
- Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
- Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:
- Faculty: Ana Felix, MD, FAAN
- Planner (Forefront Collaborative):Krista Jaworski
Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
Content Review Statement
The content of this activity was independently peer reviewed. The reviewer
of this activity has no relevant financial relationships to disclose.
This continuing medical education activity will include reference to
unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions about the Activity
Krista_jaworski@forefrontcollab.com
812-340-4274
Activity Details
Expires: July 14, 2020
Accredited By
Target Audience
This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
- Develop treatment plans in line with standards of practice for acute and preventive management of episodic and chronic migraine.
- Discuss unmet patient needs and burden of episodic and chronic migraine.
- Analyze safety and efficacy data for emerging therapies in acute and preventive treatment of migraine relative to current standards and clinically meaningful outcomes.
Activity Description
The thinking around both preventive and acute treatment of migraine is undergoing a radical change as new therapies emerge that target varied routes, some specific to known mechanisms of migraine pathophysiology. From new classes of treatment to emerging therapies and neuromodulatory devices, headache specialist and general neurologist, Stewart J. Tepper, MD, and Ana Felix, MD, FAAN, team up to provide a practical update for practicing clinicians on key treatment advances that are transforming migraine care.
Statement of Educational Need
With the recent approvals, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).
Agenda
The New Era of Migraine Treatment
Cases in Episodic and Chronic Migraine
Faculty
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Neurologist,
Assistant Professor,
Department of Internal Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must
demonstrate balance, independence, and scientific rigor. All those in a
position to control the content of an activity must disclose all relevant
financial relationship(s) with commercial interest(s)*. For this educational
activity, all conflicts of interest have been resolved through peer review
and revisions to ensure independence, evidence base, fair balance, and
absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest
as any entity producing, marketing, reselling, or distributing healthcare
goods or services consumed by or used on patients. The ACCME does not
consider providers of clinical service directly to patients to be commercial
interests.
The following individuals have disclosed that they and/or their
spouse/partner has had a financial relationship in the past 12 months:
- Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Inc, Allergan, Alphasights, Amgen, Autonomic Technologies, Inc., Axsome Therapeutics, Cefaly, Charleston Laboratories, Inc., DeepBench, Dr. Reddy’s Laboratories Ltd., electroCore, LLC, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, LLC, Magellan Rx Management, Neurolief Ltd., Nordic BioTech, Novartis, Pfizer, Scion Neurostim, LLC, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Inc., Dr. Reddy’s Laboratories, Ltd., electroCore, LLC, eNeura, Neurolief, Novartis, Scion Neurostim, LLC, Teva Pharmaceutical Industries Ltd., and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies, Inc.
- Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva PharmaceuticalIndustries Ltd.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:
- Faculty: Ana Felix, MD, FAAN
- Planner (Forefront Collaborative):Krista Jaworski
Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Forefront Collaborative designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 80%. Certificates will be generated upon completion and submission of the evaluation form.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
Content Review Statement
The content of this activity was independently peer reviewed. The reviewer
of this activity has no relevant financial relationships to disclose.
This continuing medical education activity will include reference to
unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions about the Activity
Krista_jaworski@forefrontcollab.com
812-340-4274
Are You Ready for Gene Replacement Therapy? Example from Spinal Muscular Atrophy
StartActivity Details
Genetic Counselor CEUs
Expires: June 2, 2020
Accredited By
Target Audience
U.S. geneticists and genetic counselors
International neurologists, pediatricians and geneticists
Learning Objectives
- Explain the genetic aspects of SMA
- Review the recessive nature of SMA
- Discuss SMA carrier status
- Discuss genetic screening recommendations
- Explain status of newborn testing addition to screening panel
- List states that have added newborn SMA testing
- Explore the potential implications of gene replacement therapy for SMA
- Summarize key clinical trial data on available/emerging treatments for SMA
Activity Description
Gene replacement therapy is gaining FDA approval in several therapeutic areas. In this roundtable discussion, three clinicians explain the different types of gene therapy and discuss risks and clinical trial results using spinal muscular atrophy (SMA) as an example.
Statement of Educational Need
Gene therapy is still a mystery to most clinicians. New therapies, such as gene therapy, prompt a reevaluation of the standards of care for patients with spinal muscular atrophy (SMA). Many clinicians have questions regarding SMA genetics.
Agenda
- A Patient’s Story
- Genetics of SMA
- Screening and Genetic Testing
- Treatment Options
- Gene Therapy 101
- Gene Replacement Therapy in SMA
- Panel Discussion of Common Questions
Faculty
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
- No relevant financial relationships to disclose
Assistant Professor
Department of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado
Aurora, CO
- Melissa Gibbons, MS, CGC, serves on advisory boards for Sarepta and AveXis.
Attending Physician, Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Assistant Professor of Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL
- Vamshi Rao, MD, serves on the advisory board for AveXis and is a principal investigator for a clinical trial for NS Pharma.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME/CE committee or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this live activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Genetic Counselor CEUs
The National Society of Genetic Counselors (NSGC) has authorized The France
Foundation to offer up to 0.1 CEUs or 1 Category 1 contact hour for the
activity Are You Ready for Gene Replacement Therapy? Example from SMA. The
American Board of Genetic Counseling (ABGC) will accept CEUs earned at this
program for the purposes of genetic counselor certification and
recertification.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving AMA PRA Category 1 Credit. The first 50 participants requesting NSGC CEUs are free. All others must submit $25 payment. Instructions will be sent with a link for payment within a month of completing the activity.
- Review the activity objectives and CME/CE/CEU information.
- Participate in the CME/CE/CEU activity.
- Complete the CME/CE/CEU evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect his/her professional practice, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting CME or CE credit, your certificate of credit or certificate of participation will be immediately available for download.
- If you are requesting NSGC CEU credit, The France Foundation will submit all documentation of activity completion to NSGC. Your CEU certificate will be issued by the end of the calendar year in which you complete the activity. Please note that your NSGC User ID is required to claim credit. Visit www.nsgc.org to find your user ID.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis, Inc.
Disclosure of Unlabeled Use
TFF requires CME/CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME/CE activity, please contact The
France Foundation at
Activity Details
Genetic Counselor CEUs
Expires: June 2, 2020
Accredited By
Target Audience
U.S. geneticists and genetic counselors
International neurologists, pediatricians and geneticists
Learning Objectives
- Explain the genetic aspects of SMA
- Review the recessive nature of SMA
- Discuss SMA carrier status
- Discuss genetic screening recommendations
- Explain status of newborn testing addition to screening panel
- List states that have added newborn SMA testing
- Explore the potential implications of gene replacement therapy for SMA
- Summarize key clinical trial data on available/emerging treatments for SMA
Activity Description
Gene replacement therapy is gaining FDA approval in several therapeutic areas. In this roundtable discussion, three clinicians explain the different types of gene therapy and discuss risks and clinical trial results using spinal muscular atrophy (SMA) as an example.
Statement of Educational Need
Gene therapy is still a mystery to most clinicians. New therapies, such as gene therapy, prompt a reevaluation of the standards of care for patients with spinal muscular atrophy (SMA). Many clinicians have questions regarding SMA genetics.
Agenda
- A Patient’s Story
- Genetics of SMA
- Screening and Genetic Testing
- Treatment Options
- Gene Therapy 101
- Gene Replacement Therapy in SMA
- Panel Discussion of Common Questions
Faculty
Kennedy Family Professor of Pediatrics and Medicine
Columbia University
New York, NY
- No relevant financial relationships to disclose
Assistant Professor
Department of Pediatrics
University of Colorado School of Medicine
Children’s Hospital Colorado
Aurora, CO
- Melissa Gibbons, MS, CGC, serves on advisory boards for Sarepta and AveXis.
Attending Physician, Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Assistant Professor of Pediatrics
Northwestern University
Feinberg School of Medicine
Chicago, IL
- Vamshi Rao, MD, serves on the advisory board for AveXis and is a principal investigator for a clinical trial for NS Pharma.
Conflict of Interest Policy/Disclosure Statement
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in healthcare and not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME/CE committee or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians
The France Foundation designates this live activity for a maximum of
1.25 AMA PRA Category 1 Credit(s)™. Physicians
should claim only the credit commensurate with the extent of their
participation in the activity.
Genetic Counselor CEUs
The National Society of Genetic Counselors (NSGC) has authorized The France
Foundation to offer up to 0.1 CEUs or 1 Category 1 contact hour for the
activity Are You Ready for Gene Replacement Therapy? Example from SMA. The
American Board of Genetic Counseling (ABGC) will accept CEUs earned at this
program for the purposes of genetic counselor certification and
recertification.
Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC)
may utilize activities that are certified by ACCME-accredited providers
toward their requirement for certification renewal by the ANCC. A certificate
of attendance will be provided by The France Foundation, an ACCME accredited
provider.
Method of Participation/How to Receive Credit
- There are no fees for participating in and receiving AMA PRA Category 1 Credit. The first 50 participants requesting NSGC CEUs are free. All others must submit $25 payment. Instructions will be sent with a link for payment within a month of completing the activity.
- Review the activity objectives and CME/CE/CEU information.
- Participate in the CME/CE/CEU activity.
- Complete the CME/CE/CEU evaluation form, which provides each participant with the opportunity to comment on how participating in the activity will affect his/her professional practice, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future educational needs.
- Credit documentation/reporting:
- If you are requesting CME or CE credit, your certificate of credit or certificate of participation will be immediately available for download.
- If you are requesting NSGC CEU credit, The France Foundation will submit all documentation of activity completion to NSGC. Your CEU certificate will be issued by the end of the calendar year in which you complete the activity. Please note that your NSGC User ID is required to claim credit. Visit www.nsgc.org to find your user ID.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis, Inc.
Disclosure of Unlabeled Use
TFF requires CME/CE faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
If you have questions about this CME/CE activity, please contact The
France Foundation at
Applying New Guidelines, Imaging, and Insights on Extending the Treatment Window in Acute Ischemic Stroke
StartActivity Details
1.25 contact hours
Expires: April 4, 2020
Accredited By
This continuing education activity is provided by Vindico Medical
Education.
Target Audience
The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
Physicians
- Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
- Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
- Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.
Nurses
- Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
- Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
- Assess the use of image-guided treatment to improve outcomes in patients with AIS.
Activity Description
Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.
Faculty
Activity Chair
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.
Faculty
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant
financial relationships to disclose.
Maria Gannett, MSN, CRNP
No relevant financial
relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial
relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships
to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide 1.25 contact hours for nurses.
This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.
Instructions for Receiving Credit
To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.
MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Contact Information for Questions about the Activity
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME/CNE Questions?
Contact us at CME@VindicoCME.com
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
1.25 contact hours
Expires: April 4, 2020
Accredited By
This continuing education activity is provided by Vindico Medical
Education.
Target Audience
The intended audience for this activity is neurologists, cardiologists, nurses, and other health care professionals involved in the treatment of patients with acute ischemic stroke.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
Physicians
- Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
- Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
- Incorporate the use of image-guided treatment to improve outcomes in patients with AIS.
Nurses
- Apply recently revised guidelines for the appropriate prehospital management, diagnosis, and treatment of patients with suspected acute ischemic stroke (AIS).
- Examine current practices for treatment of AIS in patients who present outside the recommended time limit for thrombolysis.
- Assess the use of image-guided treatment to improve outcomes in patients with AIS.
Activity Description
Based on the success of several new clinical trials, the American Heart Association/American Stroke Association released updated stroke treatment guidelines in 2018. The guidelines address prehospital management, diagnosis, and treatment. Key revisions include extending the treatment window for mechanical thrombectomy in eligible patients and broadening the number of patients who qualify for thrombolysis. Advances in imaging techniques and technology have improved the overall management of acute ischemic stroke (AIS), and physicians must keep apprised of how to best incorporate these findings into practice to improve patient care. This CME/CNE activity will review the revised guidelines for patients with suspected AIS and patients who present outside the recommended time limit for thrombolysis, as well as the use of image-guided treatment to improve outcomes.
Faculty
Activity Chair
Adjunct Professor, Davee Department of Neurology
Division of Vascular Neurology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
No relevant financial relationships to disclose.
Faculty
Director, Stanford Stroke Center
Coyote Foundation Professor of Neurology and
Neurological Sciences
Stanford University Medical Center
Stanford, CA
Disclosures
Consulting Fee: Genentech, iSchemaView, Medtronic
Ownership Interest: iSchemaView
Chief of System Research
Mission Research Institute/Mission Health
Asheville, NC
Disclosures
Consulting Fee: Biogen
Executive Vice Chair, Department of Emergency Medicine
Henry Ford Health System
Clinical Professor of Emergency Medicine, Wayne State University
Detroit, MI
Disclosures
Consulting Fee: Shire
Research Funding: NIH
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant
financial relationships to disclose.
Maria Gannett, MSN, CRNP
No relevant financial
relationships to disclose.
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial
relationships to disclose.
Staff
Vindico Medical Education
No relevant financial relationships
to disclose.
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical Education and the American Nurses Credentialing Center (ANCC) Commission on Accreditation’s Standards for Commercial Support, all CME/CNE providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers and staff involved in the development of CME/CNE content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control.
Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Vindico Medical Education, LLC, is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Vindico Medical Education will provide 1.25 contact hours for nurses.
This enduring material is approved for 1 year from the date of original release, April 5, 2019 to April 4, 2020.
Instructions for Receiving Credit
To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, watch the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Learner-Paced Continuing Nursing Education Contact Hour Certificate.
MIPS Qualifying Activity
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.
To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:
- address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
- have specific, measurable aim(s) for improvement;
- include interventions intended to result in improvement;
- include data collection and analysis of performance data to assess the impact of the interventions; and
- define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
Education activities are distinguished as separate from endorsement of commercial products. When commercial products are displayed, participants will be advised that accredited status as a provider refers only to its continuing education activities and does not imply ANCC Commission on Accreditation endorsement of any commercial products.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Contact Information for Questions about the Activity
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME/CNE Questions?
Contact us at CME@VindicoCME.com
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
SMA Management: Data, Insights and Practice
StartActivity Details
Expires: December 6, 2019
Accredited By
Target Audience
Pediatric neurologists, neurologists, neuromuscular specialists, pediatricians
Learning Objectives
- Review new information on the management of patients with SMA released at the Child Neurology Society and World Muscle Society 2018 annual meetings
- Apply new information to current SMA management practices, as relevant
Activity Description
This education provides the opportunity to learn the latest in the management of patients with Type 1 or Type 3 spinal muscular atrophy (SMA). Abstracts of posters from recent neurology meetings are presented followed by video discussions by expert faculty regarding the implication on the management of patients. Skills can then be applied in an interactive case where the learner is challenged to make decisions for a patient with Type 1 or Type 3 SMA.
Statement of Educational Need
The recent, rapid influx of information surrounding approved and emerging treatments for spinal muscular atrophy (SMA) has created a gap in clinician knowledge and the ability to apply it to practice.
Agenda
Type 1 SMA abstracts
NURTURE Update in Presymptomatic Patients (3:35)
Dr. Nancy Kuntz and Dr. Richard Finkel
Improvement for Patients in ENDEAR Study (4:07)
Dr. Nancy Kuntz and Dr. Richard Finkel
Type 1 interactive case
Type 3 SMA abstracts
Results in Type 3 Patients Treated with Nusinersen (3:05)
Dr. Richard Finkel, Dr. Nancy Kuntz, and Dr. Gyula Acsadi
A Multidisciplinary Team is Essential to the Management of SMA
(2:08)
Dr. Thomas Crawford and Dr. Laurent Servais
Type 3 interactive case
Faculty
Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Farmington, Connecticut
- Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Sarepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Sarepta.
Thomas Crawford, MD
Co-Director, Muscular Dystrophy Association Clinic
Professor of Neurology
Johns Hopkins Medicine
Baltimore, Maryland
- Dr. Crawford serves as a consultant and is on the advisory boards for AveXis, Inc., Biogen, Mallinckrodt, Marathon, Roche/Genentech, Santhera, and Scholar Rock.
Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida
- Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Roche, and Novartis. He receives clinical trial support from AveXis, Biogen, Ionis, Catabasis, Cytokinetics, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.
Nancy L. Kuntz, MD
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
- Dr. Kuntz serves on clinical advisory boards for Audentes, AveXis, Inc., Biogen, Roche, and Sarepta. She has participated in educational lectures funded by Biogen.
Laurent Servais, MD, PhD
Pediatric Neurology
Institut de Myologie
Paris, France
- Dr. Servais serves on advisory boards for AveXis, Inc., Biogen, and Roche. He is a principle investigator for projects funded by AveXis, Inc., Biogen, and Roche.
Conflict of Interest Policy/Disclosure Statement
Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France
Foundation (TFF) requires that individuals in a position to control the
content of an educational activity disclose all relevant financial
relationships with any commercial interest. TFF resolves all conflicts of
interest to ensure independence, objectivity, balance, and scientific rigor
in all its educational programs. Furthermore, TFF seeks to verify that all
scientific research referred to, reported, or used in a CME/CE activity
conforms to the generally accepted standards of experimental design, data
collection, and analysis. TFF is committed to providing learners with
high-quality CME/CE activities that promote improvements in health care and
not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
Expires: December 6, 2019
Accredited By
Target Audience
Pediatric neurologists, neurologists, neuromuscular specialists, pediatricians
Learning Objectives
- Review new information on the management of patients with SMA released at the Child Neurology Society and World Muscle Society 2018 annual meetings
- Apply new information to current SMA management practices, as relevant
Activity Description
This education provides the opportunity to learn the latest in the management of patients with Type 1 or Type 3 spinal muscular atrophy (SMA). Abstracts of posters from recent neurology meetings are presented followed by video discussions by expert faculty regarding the implication on the management of patients. Skills can then be applied in an interactive case where the learner is challenged to make decisions for a patient with Type 1 or Type 3 SMA.
Statement of Educational Need
The recent, rapid influx of information surrounding approved and emerging treatments for spinal muscular atrophy (SMA) has created a gap in clinician knowledge and the ability to apply it to practice.
Agenda
Type 1 SMA abstracts
NURTURE Update in Presymptomatic Patients (3:35)
Dr. Nancy Kuntz and Dr. Richard Finkel
Improvement for Patients in ENDEAR Study (4:07)
Dr. Nancy Kuntz and Dr. Richard Finkel
Type 1 interactive case
Type 3 SMA abstracts
Results in Type 3 Patients Treated with Nusinersen (3:05)
Dr. Richard Finkel, Dr. Nancy Kuntz, and Dr. Gyula Acsadi
A Multidisciplinary Team is Essential to the Management of SMA
(2:08)
Dr. Thomas Crawford and Dr. Laurent Servais
Type 3 interactive case
Faculty
Gyula Acsadi, MD, PhD
Division Head of Neurology and Rehabilitation
Professor of Pediatric Neurology
Connecticut Children’s Medical Center
University of Connecticut Medical School
Farmington, Connecticut
- Dr. Gyula Acsadi serves as a consultant for AveXis, Biogen, and Sarepta. He is on the speakers bureau for Biogen and conducts contract research for Biogen, Italfarmaco, and Sarepta.
Thomas Crawford, MD
Co-Director, Muscular Dystrophy Association Clinic
Professor of Neurology
Johns Hopkins Medicine
Baltimore, Maryland
- Dr. Crawford serves as a consultant and is on the advisory boards for AveXis, Inc., Biogen, Mallinckrodt, Marathon, Roche/Genentech, Santhera, and Scholar Rock.
Richard S. Finkel, MD
Division Chief of Neurology
Pediatric Neurology
Nemours Children’s Hospital
Orlando, Florida
- Dr. Richard Finkel is a consultant for AveXis, Biogen, Catabasis, Ionis, Mitobridge, Roche, and Novartis. He receives clinical trial support from AveXis, Biogen, Ionis, Catabasis, Cytokinetics, Lilly, MDA, NIH, ReveraGen, and Summit. Dr. Finkel owns stock in Roche. His partner holds several patents and receives patent licensing royalties from National Jewish Center and Children’s Hospital of Philadelphia.
Nancy L. Kuntz, MD
Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Attending Physician
Division of Neurology
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, Illinois
- Dr. Kuntz serves on clinical advisory boards for Audentes, AveXis, Inc., Biogen, Roche, and Sarepta. She has participated in educational lectures funded by Biogen.
Laurent Servais, MD, PhD
Pediatric Neurology
Institut de Myologie
Paris, France
- Dr. Servais serves on advisory boards for AveXis, Inc., Biogen, and Roche. He is a principle investigator for projects funded by AveXis, Inc., Biogen, and Roche.
Conflict of Interest Policy/Disclosure Statement
Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France
Foundation (TFF) requires that individuals in a position to control the
content of an educational activity disclose all relevant financial
relationships with any commercial interest. TFF resolves all conflicts of
interest to ensure independence, objectivity, balance, and scientific rigor
in all its educational programs. Furthermore, TFF seeks to verify that all
scientific research referred to, reported, or used in a CME/CE activity
conforms to the generally accepted standards of experimental design, data
collection, and analysis. TFF is committed to providing learners with
high-quality CME/CE activities that promote improvements in health care and
not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credit(s)™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from Biogen.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Highlights from MS Forum® V
StartActivity Details
1.75 Contact Hours
Expires: December 31, 2019
Accredited By
Endorsed By
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the treatment of patients with multiple sclerosis (MS).
Purpose/Learning Objectives
Upon successful completion of this activity, participants should be better
able to:
Physician
- Assess the latest clinical evidence regarding available and emerging DMTs for MS management.
- Identify patients with progressive MS in a timely manner to ensure appropriate intervention.
- Select treatment for patient with RRMS or progressive MS based on the latest clinical advances and evidence-based guidelines.
Nurse
- Assess the latest clinical evidence regarding available and emerging DMTs for MS management.
Activity Description
This CME/CNE activity is based on the slides and lectures presented by the faculty at the live program, “MS Forum® V: Applying Clinical Advances and Shared Decision-making to Improve Quality Care,” on October 27, 2018 at the JW Marriott Chicago in Chicago, IL.
Statement of Educational Need
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. Guidelines from the American Academy of Neurology on the use of DMTs were just released in 2018 and clinicians need to be updated on these new evidence-based recommendations. In this CME/CNE activity, Highlights from MS Forum®V, current treatment guidelines, safety, efficacy, and use of current DMTs will be discussed.
Agenda
What Do the New Guidelines Mean for Your Practice?
Updates in DMTs: Clinical and Practical Review
Updates in Progressive MS: Recognition and Management
Faculty
Activity Chair:
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:Consulting Fee: Accordant, Acorda, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva
Contracted Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis
Steering Committee & Faculty:
Director of Neuroimaging Research
MS Center at Shepherd Center
Atlanta, GA
Disclosures:Consulting Fee: Biogen, Celgene, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva
Speakers Bureau: Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Disclosures:Consulting Fee: EMD Serono, Mylan, Novartis
Contracted Research (Paid to Institution): Genentech/Hoffman LaRoche, MedDay, Novartis
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Disclosures:Consulting Fee: Bayer, Biogen, Celgene, EMD Serono, Novartis, Roche/Genentech, Sanofi/Genzyme, Teva
Associate Professor of Neurology
Vanderbilt University
Nashville, TN
Disclosures:Consulting Fee: Bayer, Biogen, Celgene, EMD Serono, Genzyme, Novartis, Teva
Speakers Bureau: Biogen, EMD Serona, Genzyme, Teva
Contracted Research: MedDay
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Nurse Planners:
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Contracted Research: Celgene, Genentech, Genzyme, Mallinckrodt, Novartis, Roche
Speakers Bureau: Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Teva
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are required
to disclose to the activity audience the relevant financial
relationships of the planners, teachers, and authors involved in the
development of CME content. An individual has a relevant financial
relationship if he or she has a financial relationship in any amount
occurring in the past 12 months with a commercial interest whose products or
services are discussed in the CME activity content over which the individual
has control.
Vindico Medical Education Staff: No relevant financial relationships to
disclose.
Signed Disclosure(s) are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for
physicians.
Vindico Medical Education, LLC is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center's Commission on
Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 1.75 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Vindico Medical Education will provide 1.75 contact hours for nurses.
Instructions for Receiving Credit
To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, review the CME/CNE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Provider-Paced Contact Hours Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and
Novartis Pharmaceuticals, Inc.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of
commercial products. When commercial products are displayed, participants
will be advised that accredited status as a provider refers only to its
continuing education activities and does not imply ANCC Commission on
Accreditation endorsement of any commercial products.
Disclaimer Statement/ Disclosure of Unlabeled Use
The material presented at or in any Vindico Medical Education and CMSC continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education and CMSC. Neither Vindico Medical Education, CMSC, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact Information for Questions About the Activity
CME@VindicoCME.com
Call us at 856-994-9400 x504
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
1.75 Contact Hours
Expires: December 31, 2019
Accredited By
Endorsed By
Target Audience
The intended audience for this activity is neurologists, neurology nurses, and other health care professionals involved in the treatment of patients with multiple sclerosis (MS).
Purpose/Learning Objectives
Upon successful completion of this activity, participants should be better
able to:
Physician
- Assess the latest clinical evidence regarding available and emerging DMTs for MS management.
- Identify patients with progressive MS in a timely manner to ensure appropriate intervention.
- Select treatment for patient with RRMS or progressive MS based on the latest clinical advances and evidence-based guidelines.
Nurse
- Assess the latest clinical evidence regarding available and emerging DMTs for MS management.
Activity Description
This CME/CNE activity is based on the slides and lectures presented by the faculty at the live program, “MS Forum® V: Applying Clinical Advances and Shared Decision-making to Improve Quality Care,” on October 27, 2018 at the JW Marriott Chicago in Chicago, IL.
Statement of Educational Need
Multiple sclerosis (MS) is a chronic, often disabling disease that attacks the central nervous system. The management of patients with MS is highly complex and the development of disease-modifying therapies (DMTs) has dramatically altered the treatment paradigm. Guidelines from the American Academy of Neurology on the use of DMTs were just released in 2018 and clinicians need to be updated on these new evidence-based recommendations. In this CME/CNE activity, Highlights from MS Forum®V, current treatment guidelines, safety, efficacy, and use of current DMTs will be discussed.
Agenda
What Do the New Guidelines Mean for Your Practice?
Updates in DMTs: Clinical and Practical Review
Updates in Progressive MS: Recognition and Management
Faculty
Activity Chair:
Professor and Vice Chair (Clinical Affairs)
Department of Neurology
Director
Multiple Sclerosis Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY
Disclosures:Consulting Fee: Accordant, Acorda, Bayer, Biogen, Celgene, Genentech/Roche, Genzyme/Sanofi, Novartis, Serono, Teva
Contracted Research: Actelion, Alkermes, Genentech/Roche, MedDay, NINDS, Novartis
Steering Committee & Faculty:
Director of Neuroimaging Research
MS Center at Shepherd Center
Atlanta, GA
Disclosures:Consulting Fee: Biogen, Celgene, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva
Speakers Bureau: Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, Teva
Professor of Neurology
Northwestern University
Feinberg School of Medicine
Director
Northwestern Comprehensive Multiple Sclerosis Program
Chicago, IL
Disclosures:Consulting Fee: EMD Serono, Mylan, Novartis
Contracted Research (Paid to Institution): Genentech/Hoffman LaRoche, MedDay, Novartis
Associate Professor of Neurology
Director, Multiple Sclerosis Center
Hospital of the University of Pennsylvania
Perelman School of Medicine
Philadelphia, PA
Disclosures:Consulting Fee: Bayer, Biogen, Celgene, EMD Serono, Novartis, Roche/Genentech, Sanofi/Genzyme, Teva
Associate Professor of Neurology
Vanderbilt University
Nashville, TN
Disclosures:Consulting Fee: Bayer, Biogen, Celgene, EMD Serono, Genzyme, Novartis, Teva
Speakers Bureau: Biogen, EMD Serona, Genzyme, Teva
Contracted Research: MedDay
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Nurse Planners:
Barbara A. Niedz, PhD, RN, CPHQ
No relevant financial relationships to disclose.
Amy Perrin Ross, APN, MSN, CNRN, MSCN
Contracted Research: Celgene, Genentech, Genzyme, Mallinckrodt, Novartis, Roche
Speakers Bureau: Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novartis, Teva
Conflict of Interest Policy/Disclosure Statement
In accordance with the Accreditation Council for Continuing Medical
Education’s Standards for Commercial Support, all CME providers are required
to disclose to the activity audience the relevant financial
relationships of the planners, teachers, and authors involved in the
development of CME content. An individual has a relevant financial
relationship if he or she has a financial relationship in any amount
occurring in the past 12 months with a commercial interest whose products or
services are discussed in the CME activity content over which the individual
has control.
Vindico Medical Education Staff: No relevant financial relationships to
disclose.
Signed Disclosure(s) are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for
physicians.
Vindico Medical Education, LLC is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center's Commission on
Accreditation.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum
of 1.75 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their
participation in the activity.
Vindico Medical Education will provide 1.75 contact hours for nurses.
Instructions for Receiving Credit
To participate in this CME/CNE activity, you must read the objectives, answer the pretest questions, review the CME/CNE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or Provider-Paced Contact Hours Certificate.
Statement of Commercial Support
This activity is supported by educational grants from Genentech, Inc. and
Novartis Pharmaceuticals, Inc.
There is no non-commercial support for this activity.
Education activities are distinguished as separate from endorsement of
commercial products. When commercial products are displayed, participants
will be advised that accredited status as a provider refers only to its
continuing education activities and does not imply ANCC Commission on
Accreditation endorsement of any commercial products.
Disclaimer Statement/ Disclosure of Unlabeled Use
The material presented at or in any Vindico Medical Education and CMSC continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education and CMSC. Neither Vindico Medical Education, CMSC, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the U.S. Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Contact Information for Questions About the Activity
CME@VindicoCME.com
Call us at 856-994-9400 x504
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Rethinking Migraine Treatment: Highlights and Recent Advances
StartActivity Details
Expires: December 10, 2019
Accredited By
Target Audience
This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
- Describe major emerging acute and preventive migraine therapies.
Activity Description
Paradigm shift, or shattered? The thinking around both preventive and acute treatment of migraine is amidst a radical change. From a new class of treatment targeting disease-specific pathophysiology to emerging therapies incorporating neuromodulatory devices, Stewart Tepper, MD, gets practicing clinicians up to speed in a Hot Topics Webinar that details the key treatment advances transforming migraine care.
Statement of Educational Need
With the recent approvals of new breakthroughs, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).
Agenda
New Horizons in Headache Treatment
Pathophysiology and Neurotransmitter Targets
New Devices and Medications for Delivering Medications
New Acute Treatment Classes
Prevention: MABs
Neuromodulation for Headache
Faculty
Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
- Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management, Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.
- Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:
- Planner (Forefront Collaborative): Katie Detzler
Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Forefront Collaborative designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 3 out of 3. Certificates will be generated upon completion and submission of the evaluation form.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
Content Review Statement
The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.
This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions about the Activity
Lily_Zurkovsky@forefrontcollab.com
317.846.2770
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
Expires: December 10, 2019
Accredited By
Target Audience
This activity is designed for general neurologists and headache specialists. Other healthcare professionals, including physician assistants, nurse practitioners, nurses, and pharmacists, who treat patients with headache may also benefit from participation in the educational activity.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe new advances in the pathophysiology of migraine, a chronic neurologic disease.
- Describe major emerging acute and preventive migraine therapies.
Activity Description
Paradigm shift, or shattered? The thinking around both preventive and acute treatment of migraine is amidst a radical change. From a new class of treatment targeting disease-specific pathophysiology to emerging therapies incorporating neuromodulatory devices, Stewart Tepper, MD, gets practicing clinicians up to speed in a Hot Topics Webinar that details the key treatment advances transforming migraine care.
Statement of Educational Need
With the recent approvals of new breakthroughs, neurologists are faced with two challenges: staying abreast of the rapidly expanding evidence base to inform acute and preventive treatment of migraine (knowledge-based gaps) and interpreting data of approved and investigational therapies to best guide clinical decision-making (competency-based gaps).
Agenda
New Horizons in Headache Treatment
Pathophysiology and Neurotransmitter Targets
New Devices and Medications for Delivering Medications
New Acute Treatment Classes
Prevention: MABs
Neuromodulation for Headache
Faculty
Professor of Neurology
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire
Conflict of Interest Policy/Disclosure Statement
Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.
*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:
- Faculty: Stewart J. Tepper, MD, has received salary from Dartmouth-Hitchcock Medical Center and from the American Headache Society and royalties from Springer; he has been a consultant or on an advisory board for Acorda Therapeutics, Alder BioPharmaceuticals, Alexza Pharmaceuticals, Allergan, Alphasights, Amgen, Autonomic Technologies, Axsome Therapeutics, Cefaly, Charleston Laboratories, DeepBench, Dr. Reddy’s Laboratories, electroCore, Eli Lilly and Company, eNeura, GLG Pharma, Guidepoint Global, Magellan Rx Management, Neurolief, Nordic BioTech, Pfizer, Scion Neurostim, Slingshot Insights, Supernus Pharmaceuticals, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; Dr. Tepper has contracted research for Alder BioPharmaceuticals, Allergan, Amgen, Autonomic Technologies, Dr. Reddy’s Laboratories, electroCore, eNeura, Scion Neurostim, Teva Pharmaceutical Industries, and Zosano Pharma Corporation; he has ownership interest in Autonomic Technologies.
- Planner (Forefront Collaborative): Lily Zurkovsky, PhD, has disclosed that she has personal stock in Teva Pharmaceutical Industries.
The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this continuing education activity:
- Planner (Forefront Collaborative): Katie Detzler
Accreditation Statement
Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Forefront Collaborative designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
Participants must complete and submit the online CME evaluation form at the conclusion of the activity and achieve a passing score of 3 out of 3. Certificates will be generated upon completion and submission of the evaluation form.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Disclaimer
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.
Content Review Statement
The content of this activity was independently peer reviewed. The reviewer of this activity has no relevant financial relationships to disclose.
This continuing medical education activity will include reference to unlabeled or unapproved uses of drugs or devices.
Contact Information for Questions about the Activity
Lily_Zurkovsky@forefrontcollab.com
317.846.2770
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
From Bench to Bedside: Gene Therapy Approaches for Rare Diseases
StartActivity Details
Expires: November 14, 2019
Accredited By
Target Audience
Pediatric Neurologists, Neurologists, Neuromuscular Specialists, Pediatricians
Learning Objectives
- Understand importance of early diagnosis for inherited neuromuscular diseases
- Explore potential implications of gene therapy
- Summarize key clinical trial data on emerging gene therapies
- Provide appropriate counseling to affected individuals and families
Activity Description
Gene replacement therapy is emerging as a potential treatment for rare CNS diseases. In this recorded CME satellite symposium to the 2018 Child Neurology Society’s annual meeting, a parent of a child with spinal muscular atrophy describes their journey through gene therapy clinical trials. Using spinal muscular atrophy as an example, Dr. Samiah Al-Zaidy, Mr. Jaysson Eicholtz and Dr. Jerry Mendell walk through the history of gene therapy from the bench to the bedside, answering questions on safety and long-term durability of this emerging treatment.
Statement of Educational Need
Gene replacement therapy is showing promising results for several neurologic diseases. Clinicians must be comfortable with this technology before it comes to the clinic. Delayed diagnosis is a common problem with spinal muscular atrophy, even when specialists are involved. Identification of the neuromotor deficits associated with SMA (and other inherited neuromuscular diseases) is often inaccurate or delayed. Prompt diagnosis and treatment is crucial in the effectiveness of gene replacement therapy. These emerging new therapies prompt a reevaluation of current standards of care for patients with SMA and appropriate counseling to the affected individuals and families.
Agenda
Introduction (Dr. Samiah Al-Zaidy)
Patient Journey Video: Meet the Villarreal family
History of Gene Therapy and the Current Landscape (Dr. Samiah Al-Zaidy)
Patient Journey Video: Diagnosis
Bringing the Vector to the Clinic (Mr. Jaysson Eicholtz)
Patient Journey Video: Treatment
Gene Therapy Clinical Trials: the Epitome of Personalized Medicine (Dr. Jerry
Mendell)
Patient Journey Video: Results
Gene Therapy Clinical Trials: Part 2 (Dr. Jerry Mendell)
Panel Discussion (Dr. Samiah Al-Zaidy, Dr. Jerry Mendell, Mr. Jaysson
Eicholtz)
Patient Journey Video: Living with SMA
Focus on Patient-Centered Care (Dr. Samiah Al-Zaidy, Dr. Jerry Mendell)
Faculty
Pediatric Neuromuscular Specialist
Formerly of Nationwide Children’s Hospital
Columbus, OH
- Dr. Al-Zaidy serves as a consultant for AveXis, Inc.
Former Director of GMP Operations
Nationwide Children’s Hospital
Columbus, OH
- Mr. Eicholtz has no relevant financial relationships to disclose.
Curran-Peters Chair of Pediatric Research
Professor of Pediatrics and Neurology
Nationwide Children’s Hospital and
The Ohio State University
Research Institute at Nationwide Children's Hospital
Columbus, OH
- Dr. Mendell serves as a consultant to AveXis, Inc., Exonics, Myonexus, and Sarepta Therapeutics. He is the principal investigator of the AVXS-101 gene therapy clinical trial, the Eteplirsen clinical trial, and an advisor on the CRISPR clinical trial.
Conflict of Interest Policy/Disclosure Statement
Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France
Foundation (TFF) requires that individuals in a position to control the
content of an educational activity disclose all relevant financial
relationships with any commercial interest. TFF resolves all conflicts of
interest to ensure independence, objectivity, balance, and scientific rigor
in all its educational programs. Furthermore, TFF seeks to verify that all
scientific research referred to, reported, or used in a CME/CE activity
conforms to the generally accepted standards of experimental design, data
collection, and analysis. TFF is committed to providing learners with
high-quality CME/CE activities that promote improvements in health care and
not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis, Inc.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.
Activity Details
Expires: November 14, 2019
Accredited By
Target Audience
Pediatric Neurologists, Neurologists, Neuromuscular Specialists, Pediatricians
Learning Objectives
- Understand importance of early diagnosis for inherited neuromuscular diseases
- Explore potential implications of gene therapy
- Summarize key clinical trial data on emerging gene therapies
- Provide appropriate counseling to affected individuals and families
Activity Description
Gene replacement therapy is emerging as a potential treatment for rare CNS diseases. In this recorded CME satellite symposium to the 2018 Child Neurology Society’s annual meeting, a parent of a child with spinal muscular atrophy describes their journey through gene therapy clinical trials. Using spinal muscular atrophy as an example, Dr. Samiah Al-Zaidy, Mr. Jaysson Eicholtz and Dr. Jerry Mendell walk through the history of gene therapy from the bench to the bedside, answering questions on safety and long-term durability of this emerging treatment.
Statement of Educational Need
Gene replacement therapy is showing promising results for several neurologic diseases. Clinicians must be comfortable with this technology before it comes to the clinic. Delayed diagnosis is a common problem with spinal muscular atrophy, even when specialists are involved. Identification of the neuromotor deficits associated with SMA (and other inherited neuromuscular diseases) is often inaccurate or delayed. Prompt diagnosis and treatment is crucial in the effectiveness of gene replacement therapy. These emerging new therapies prompt a reevaluation of current standards of care for patients with SMA and appropriate counseling to the affected individuals and families.
Agenda
Introduction (Dr. Samiah Al-Zaidy)
Patient Journey Video: Meet the Villarreal family
History of Gene Therapy and the Current Landscape (Dr. Samiah Al-Zaidy)
Patient Journey Video: Diagnosis
Bringing the Vector to the Clinic (Mr. Jaysson Eicholtz)
Patient Journey Video: Treatment
Gene Therapy Clinical Trials: the Epitome of Personalized Medicine (Dr. Jerry
Mendell)
Patient Journey Video: Results
Gene Therapy Clinical Trials: Part 2 (Dr. Jerry Mendell)
Panel Discussion (Dr. Samiah Al-Zaidy, Dr. Jerry Mendell, Mr. Jaysson
Eicholtz)
Patient Journey Video: Living with SMA
Focus on Patient-Centered Care (Dr. Samiah Al-Zaidy, Dr. Jerry Mendell)
Faculty
Pediatric Neuromuscular Specialist
Formerly of Nationwide Children’s Hospital
Columbus, OH
- Dr. Al-Zaidy serves as a consultant for AveXis, Inc.
Former Director of GMP Operations
Nationwide Children’s Hospital
Columbus, OH
- Mr. Eicholtz has no relevant financial relationships to disclose.
Curran-Peters Chair of Pediatric Research
Professor of Pediatrics and Neurology
Nationwide Children’s Hospital and
The Ohio State University
Research Institute at Nationwide Children's Hospital
Columbus, OH
- Dr. Mendell serves as a consultant to AveXis, Inc., Exonics, Myonexus, and Sarepta Therapeutics. He is the principal investigator of the AVXS-101 gene therapy clinical trial, the Eteplirsen clinical trial, and an advisor on the CRISPR clinical trial.
Conflict of Interest Policy/Disclosure Statement
Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The France
Foundation (TFF) requires that individuals in a position to control the
content of an educational activity disclose all relevant financial
relationships with any commercial interest. TFF resolves all conflicts of
interest to ensure independence, objectivity, balance, and scientific rigor
in all its educational programs. Furthermore, TFF seeks to verify that all
scientific research referred to, reported, or used in a CME/CE activity
conforms to the generally accepted standards of experimental design, data
collection, and analysis. TFF is committed to providing learners with
high-quality CME/CE activities that promote improvements in health care and
not those of a commercial interest.
Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, or other members at
The France Foundation who control content have no relevant financial
relationships to disclose.
Accreditation Statement
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The France Foundation designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.
Instructions for Receiving Credit
- There are no fees for participating in and receiving credit for this activity.
- Review the activity objectives and CME/CE information.
- Complete the CME/CE activity
- Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
- Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
- Credit documentation/reporting:
-
- If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
Statement of Commercial Support
This activity is supported by an educational grant from AveXis, Inc.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Contact Information
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.
Hardware/Software Requirements
Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.